Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

2387 - Analysis of the relationship between heading N / L and survival in patients treated with Immunotherapy in lung cancer

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Noemi De Dios Alvare

Citation

Annals of Oncology (2018) 29 (suppl_8): viii493-viii547. 10.1093/annonc/mdy292

Authors

N. De Dios Alvare1, M. Costa Rivas1, S. Agraso Busto2, A. Alonso Herrero3, M.J. Villanueva Silva3, D. Pereiro Corbacho4, C. GarcÍa Benito1

Author affiliations

  • 1 Oncology, Hospital Universitario Alvaro Cunqueiro, 36312 - Vigo/ES
  • 2 Oncology, Hospital Universitario Alvaro Cunqueiro, 36VI36 - Vigo/ES
  • 3 Oncology, Hospital Universitario Alvaro Cunqueiro, 36 - Vigo/ES
  • 4 Oncology, hospital Universitario Alvaro Cunqueiro, 36 - Vigo/ES
More

Resources

Abstract 2387

Background

The neutrophil-lymphocyte (N / L) ratio is a marker of general immune response in different stress situations, having shown a relationship between the quotient and the evolution of patients treated with immunotherapy (IT), emphasizing the importance of inflammation in these patients.

Methods

In order to evaluate this relationship in a context of usual clinical practice, a retrospective review of patients with pulmonary neoplasia who received IT treatment in the first line or successive, between November 2015 and December 2017. Data were collected from the clinical history, with attention to baseline neutrophil and lymphocyte numbers, objective response by criteria iRECIST 1.1 and overall survival (OS) defined from the beginning of treatment until death.

Results

Sixty-six patients (22 women and 44 men) with a mean age of 64 years (44-78) were analyzed. 9.1%, 9 patients (p) received immunotherapy as first line treatment, 69.7% (46p) received it as 2nd line and 21.2% (14p) as 3rd line treatment. Regarding the type of IT, 49p (74.2%) received treatment with Nivolumab and 17p (25.8%) were treated with Pembrolizumab. Two stretches of baseline N / L ratios < = 5 (low) and> 5 (high) were defined. Low ratio N / L ( < =5) was identified in 47p (71.2%) of the patients treated with IT and high ratio N/L (> 5) in 19p (20.8%). Of the 47 patients with a low ratio: 22p (46.8%) had some type of response or stabilization of their disease, 15p (31.9%) had progression and 10p (21.3%) received less than months of treatment, 5p for PS reorientation and the other 5p continue with the treatment and are pending reevaluation. Among the 19p patients with high N / L quotient: 4p (21.1%) presented response or stabilization of the disease, 15p (78.9%) presented progression or treatment was interrupted due to deterioration of the ECOG. The average survival in the group with a low N / L ratio ( < = 5) was 87.85 weeks compared to the group with a high N / L ratio (> 5) 25.74 weeks (p < 0.05).

Conclusions

The N / L ratio has been identified in some studies as an adverse prognostic factor in patients treated with IT. Our data from the usual clinical practice support this theory. If these findings are confirmed in future studies, it could be used as a response biomarker for better patient selection.

Clinical trial identification

Legal entity responsible for the study

Fundación Biomédica Galicia Sur.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.